Aβ Monoclonal Antibody Drug - Global Market Insights and Sales Trends 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Aβ Monoclonal Antibody Drug - Global Market Insights and Sales Trends 2024
Aβ monoclonal antibody drugs are a type of drug used to treat Alzheimer's disease. Their function is to target the accumulation and deposition of β-amyloid protein (Aβ, or β-amyloid precursor protein). Slow or stop the progression of the disease.
Alzheimer's disease is a neurodegenerative disease, one of its main characteristics is the abnormal deposition of Aβ protein in the brain, forming β-amyloid plaques between neurons. These plaques are associated with cognitive decline and neuronal damage, so researchers seek to develop drugs to interfere with Aβ accumulation in the hope of slowing or curing Alzheimer's disease.
The global Aβ Monoclonal Antibody Drug market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2024 to 2029. The market is mainly driven by the significant applications of Aβ Monoclonal Antibody Drug in various end use industries. The expanding demands from the Hospital and Clinic, are propelling Aβ Monoclonal Antibody Drug market. Aducanumab, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Lecanemab segment is estimated at % CAGR for the next seven-year period.
Asia Pacific shows high growth potential for Aβ Monoclonal Antibody Drug market, driven by demand from China, the second largest economy with some signs of stabilising, the Aβ Monoclonal Antibody Drug market in China is forecast to reach US$ million by 2029, trailing a CAGR of % over the 2024-2034 period, while the U.S. market will reach US$ million by 2029, exhibiting a CAGR of % during the same period.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Aβ Monoclonal Antibody Drug, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study
This report provides in-depth analysis of the global Aβ Monoclonal Antibody Drug market, and provides market size (US$ million) and CAGR for the forecast period (2024-2034), considering 2022 as the base year.
This report profiles key players in the global Aβ Monoclonal Antibody Drug market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Aβ Monoclonal Antibody Drug sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Aβ Monoclonal Antibody Drug covered in this report include Eisai, Biogen and Eli Lilly & Co., etc.
The global Aβ Monoclonal Antibody Drug market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles
Eisai
Biogen
Eli Lilly & Co.
Global Aβ Monoclonal Antibody Drug market, by region
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Aβ Monoclonal Antibody Drug market, Segment by Type
Aducanumab
Lecanemab
Donanemab
Global Aβ Monoclonal Antibody Drug market, by Application
Hospital
Clinic
Core Chapters
Chapter OneIntroduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter TwoDetailed analysis of Aβ Monoclonal Antibody Drug manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter ThreeSales, revenue of Aβ Monoclonal Antibody Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter FourIntroduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and NineNorth America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter TenProvides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter ElevenAnalysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter TwelveAnalysis of sales channel, distributors and customers.
Chapter ThirteenResearch Findings and Conclusion.
Alzheimer's disease is a neurodegenerative disease, one of its main characteristics is the abnormal deposition of Aβ protein in the brain, forming β-amyloid plaques between neurons. These plaques are associated with cognitive decline and neuronal damage, so researchers seek to develop drugs to interfere with Aβ accumulation in the hope of slowing or curing Alzheimer's disease.
The global Aβ Monoclonal Antibody Drug market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2024 to 2029. The market is mainly driven by the significant applications of Aβ Monoclonal Antibody Drug in various end use industries. The expanding demands from the Hospital and Clinic, are propelling Aβ Monoclonal Antibody Drug market. Aducanumab, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Lecanemab segment is estimated at % CAGR for the next seven-year period.
Asia Pacific shows high growth potential for Aβ Monoclonal Antibody Drug market, driven by demand from China, the second largest economy with some signs of stabilising, the Aβ Monoclonal Antibody Drug market in China is forecast to reach US$ million by 2029, trailing a CAGR of % over the 2024-2034 period, while the U.S. market will reach US$ million by 2029, exhibiting a CAGR of % during the same period.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Aβ Monoclonal Antibody Drug, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study
This report provides in-depth analysis of the global Aβ Monoclonal Antibody Drug market, and provides market size (US$ million) and CAGR for the forecast period (2024-2034), considering 2022 as the base year.
This report profiles key players in the global Aβ Monoclonal Antibody Drug market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Aβ Monoclonal Antibody Drug sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Aβ Monoclonal Antibody Drug covered in this report include Eisai, Biogen and Eli Lilly & Co., etc.
The global Aβ Monoclonal Antibody Drug market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles
Eisai
Biogen
Eli Lilly & Co.
Global Aβ Monoclonal Antibody Drug market, by region
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Aβ Monoclonal Antibody Drug market, Segment by Type
Aducanumab
Lecanemab
Donanemab
Global Aβ Monoclonal Antibody Drug market, by Application
Hospital
Clinic
Core Chapters
Chapter OneIntroduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter TwoDetailed analysis of Aβ Monoclonal Antibody Drug manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter ThreeSales, revenue of Aβ Monoclonal Antibody Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter FourIntroduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and NineNorth America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter TenProvides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter ElevenAnalysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter TwelveAnalysis of sales channel, distributors and customers.
Chapter ThirteenResearch Findings and Conclusion.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices